Since hippocampal neurogenesis persists in the aged and diseased human brain (Tobin et al., 2019), enhancing neuronal CX3CL1, mainly the C-terminal fragment, may well be a viable therapeutic strategy for blocking or reversing neuronal loss in the treatment of patients with Alzheimer's disease or related neurodegenerative diseases. The gene discussed is CX3CL1; the disease is early-onset autosomal dominant Alzheimer disease.